STAT3 and neoplasm: In contrast, the combination of STAT3 inhibitors with PD-L1 inhibitors has been shown to promote PD-L1 expression and suppress the immune response instead, which leads to the reduction in the anti-tumor effect of the anti-PD-L1 antibody [273,274].